The Human Papillomavirus Type 16 E6 and E7 Oncoproteins Dissociate Cellular Telomerase Activity from the Maintenance of Telomere Length

The “high risk” subgroup of human papillomaviruses (e.g. HPV-16 and HPV-18) infect and induce tumors of mucosal epithelium. These neoplasms, which can progress to malignancy, retain and express the papillomavirus E6 andE7 oncogenes. In vitro, the E6 and E7 proteins associate with the cellular p53 and Rb proteins and interfere with their normal growth-regulatory functions. We report here that primary human keratinocytes transduced with the HPV-16 E6 gene, but not the E7 gene, express significant telomerase activity. However, despite this detectable enzymatic activity,E6-transduced cells continue to shorten their telomeres during in vitro passaging similar to control cells and to cells expressing the E7 and E6+E7 genes. At late passages, however, E7-transduced cells partially restore telomere(definition) length, although they lack detectable telomerase activity, demonstrating that E6-independent, telomerase-independent events mediate this change. The “high risk” subgroup of human papillomaviruses (e.g. HPV-16 and HPV-18) infect and induce tumors of mucosal epithelium. These neoplasms, which can progress to malignancy, retain and express the papillomavirus E6 andE7 oncogenes. In vitro, the E6 and E7 proteins associate with the cellular p53 and Rb proteins and interfere with their normal growth-regulatory functions. We report here that primary human keratinocytes transduced with the HPV-16 E6 gene, but not the E7 gene, express significant telomerase activity. However, despite this detectable enzymatic activity,E6-transduced cells continue to shorten their telomeres during in vitro passaging similar to control cells and to cells expressing the E7 and E6+E7 genes. At late passages, however, E7-transduced cells partially restore telomere length, although they lack detectable telomerase activity, demonstrating that E6-independent, telomerase-independent events mediate this change. The human papillomaviruses (HPVs) 1The abbreviations used are: HPV, human papillomavirus; TRAP; telomeric amplification protocol; kb, kilobase(s). 1The abbreviations used are: HPV, human papillomavirus; TRAP; telomeric amplification protocol; kb, kilobase(s).associated with cervical cancer are designated as the “high risk” subgroup of HPVs (e.g. HPV-16 and 18) (1zur Hausen H. Virology. 1991; 184: 9-13Crossref PubMed Scopus (857) Google Scholar) and encode two viral oncogenes, E6 and E7, which exhibit immortalizing and transforming activities in various rodent and human cell types (2–14; reviewed in Refs. 15Mansur C.P. Androphy E.J. Biochem. Biophys. Acta. 1993; 1155: 323-345PubMed Google Scholar and 16Stöppler H. Conrad Stöppler M. Schlegel R. Intervirology. 1994; 37: 168-179Crossref PubMed Scopus (26) Google Scholar). The oncogenic potential of these proteins is due, at least in part, to their ability to interfere with the function of two cellular tumor suppressor proteins, p53 and the retinoblastoma susceptibility gene product, Rb. The E6 protein binds to the cellular p53 protein and promotes its ubiquitin-dependent degradation (17Scheffner M. Werness B.A. Huibregtse J.M. Levine A.J. Howley P.M. Cell. 1990; 63: 1129-1136Abstract Full Text PDF PubMed Scopus (3444) Google Scholar, 18Werness B.A. Levine A.J. Howley P.M. Science. 1990; 248: 76-79Crossref PubMed Scopus (2158) Google Scholar). E7 protein associates with Rb and interferes with its binding to E2F, resulting in impaired Rb cell cycle control functions (19Heck D.V. Yee C.L. Howley P.M. Münger K. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 4442-4446Crossref PubMed Scopus (297) Google Scholar, 20Dyson N. Howley P.M. Münger K. Harlow E. Science. 1989; 243: 934-937Crossref PubMed Scopus (2388) Google Scholar, 21Dyson N. Guida P. Münger K. Harlow E. J. Virol. 1992; 66: 6893-6902Crossref PubMed Google Scholar). The natural host cell of these viruses, the keratinocyte, is immortalized by the efficient expression of E7 protein (22Halbert C.L. Demers G.W. Galloway D.A. J. Virol. 1991; 65: 473-478Crossref PubMed Google Scholar). Although the E6 protein cannot independently immortalize these cells, it greatly augments the biological activity of the E7 protein (23Barbosa M.S. Schlegel R. Oncogene. 1989; 4: 1529-1532PubMed Google Scholar), induces resistance to signals for terminal differentiation (24Sherman L. Schlegel R. J. Virol. 1996; 70: 3269-3279Crossref PubMed Google Scholar), and prolongs precrisis life span (25Klingelhutz A.J. Barber S.A. Smith P.P. Dyer K. McDougall J.K. Mol. Cell. Biol. 1994; 14: 961-969Crossref PubMed Scopus (176) Google Scholar). Recently, it has been demonstrated that the expression ofE6in primary human keratinocytes leads to an activation of telomerase (26Klingelhutz A.J. Foster S.A. McDougall J.K. Nature. 1996; 380: 79-82Crossref PubMed Scopus (699) Google Scholar), an enzyme capable of preventing the shortening of telomeres during DNA replication (27Blackburn E.H. Szostak J.W. Annu. Rev. Biochem. 1984; 53: 163-194Crossref PubMed Scopus (506) Google Scholar, 28Blackburn E.H. Nature. 1991; 350: 569-573Crossref PubMed Scopus (3042) Google Scholar, 29Lindsey J. McGill N.I. Lindsey L.A. Green D.K. Cooke H.J. Mutat. Res. 1991; 256: 45-48Crossref PubMed Scopus (407) Google Scholar, 30Harley C.B. Mutat. Res. 1991; 256: 271-282Crossref PubMed Scopus (1082) Google Scholar, 31Zakian V.A. Annu. Rev. Genet. 1989; 23: 579-604Crossref PubMed Scopus (530) Google Scholar). Telomeres, the ends of human eucaryotic chromosomes, are shortened progressively during cell aging in vivo and in vitro (29Lindsey J. McGill N.I. Lindsey L.A. Green D.K. Cooke H.J. Mutat. Res. 1991; 256: 45-48Crossref PubMed Scopus (407) Google Scholar, 30Harley C.B. Mutat. Res. 1991; 256: 271-282Crossref PubMed Scopus (1082) Google Scholar, 32Harley C.B. Futcher A.B. Greider C.W. Nature. 1990; 345: 458-460Crossref PubMed Scopus (4587) Google Scholar, 33Hastie N.D. Dempster M. Dunlop M.G. Thompson A.M. Green D.K. Allshire R.C. Nature. 1990; 346: 866-868Crossref PubMed Scopus (1471) Google Scholar